“It often feels as if I have lived at the eye hospital more than at home, due to surgeries, complications, and emergency visits.” This is the story from Marie Olsson, 44 years old from a small town called Katrineholm in Sweden, who was born with an eye condition called aniridia.
restorevision@catalyze-group.com
Restore Vision’s latest progress
Where do we stand now in our journey of advancing treatments for rare eye diseases in Europe?
A journey of resilience and adaptability – life with aniridia
Today it’s World Sight Day – a global awareness day dedicated to the importance of eye health, vision care, and the prevention of blindness and visual impairment.
Behind this message are real-life stories of people dealing with visual impairment. Today, we share the story of Irma, 38 years old, originally from Lithuania, and mother of two children – a daughter of 12 and son of 8 years old. Her son was born with a rare genetic eye condition, called aniridia.
New study: Enhancing Immune Modulation with “trained” MSC-EVs
In this study, the Restore Vision team at Galway explored whether EVs from MSCs that were specially “trained” using two immune-related proteins – TGF-β1 and IFN-γ – could more effectively regulate the immune system than EVs from untrained cells.
Join our Patients Working Group!
Are you living with a rare eye disease? Or are you a caretaker of someone who is? Join the Patients Working Group of the international research project Restore Vision! [Available in EN, IT, ES, FR, SE, DE]
New study: mineralocorticoid receptor antagonism improves corneal integrity in a rat model of limbal stem cell deficiency
In this new study, our team at INSERM, explored whether mineralocorticoid receptor antagonists (MRAs)—commonly used for heart and kidney conditions—could aid corneal repair in limbal stem cell deficiency (LSCD), a rare and difficult-to-treat eye disease.
New study: the role of Mesenchymal Stromal Cells and Apoptotic Bodies in immune regulation
Research has shown that MSC-derived ApoBDs can help regulate the immune system, however they have not been studied as much as smaller extracellular vesicles. To fill in the gap, our team at Galway conducted a study to explore the therapeutic potential of large and small ApoBDs.
Healing the cornea: the therapeutic potential of Mesenchymal Stromal Cells and their Extracellular Vesicles
In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Restore Vision’s first review meeting
On January, 16 the RESTORE VISION team held its first review meeting to assess project progress and discuss plans for the upcoming year.